These next-generation GLP-1-based therapeutics for metabolic diseases, either already available or approaching clinical approval, appear to enhance the metabolic and weight-reducing efficacy compared to existing GLP-1RAs. The gene discussed is GCG; the disease is Other metabolic disease.